Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 25, 2026

T-Mobile Turns up the Value With the Samsung Galaxy S26 Lineup

View original at finance.yahoo.com
T-Mobile Turns up the Value With the Samsung Galaxy S26 Lineup Samsung’s newest Galaxy devices land at T-Mobile — with on Us offers, benefits worth switching for and a five-year price guarantee Get 5G Home Internet delivered same-day and bundle with a new Galaxy S26 for even more savings BELLEVUE, Wash., February 25, 2…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • T-Mobile's 5G Advanced network unlocks the full performance of the Galaxy S26, turning features like multi-carrier aggregation and uplink enhancements into noticeable real-world improvements in speed, responsiveness and reliability

    80% confidence

  • T-Mobile's 5G network provides quicker uploads and downloads for large files and smooth 4K streaming even in crowded places like airports and events

    80% confidence

  • Combined with built-in benefits and a 5-year price guarantee on best plans, T-Mobile offers unmatched performance and value not found anywhere else

    80% confidence

  • This is T-Mobile's richest Galaxy offer ever and the first time T-Mobile customers can get the Galaxy S26 Ultra on Us

    80% confidence

  • SuperMobile is the best business plan on the best network

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com